[Inhibition of angiogenesis by proteins, peptides and "small molecules"].
Jayson
Gordon
G
Cancer Research UK, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Armand
Jean-Pierre
JP
Berdel
Wolfgang E
WE
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D016503:Drug Delivery Systems; D006801:Humans; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000401:mortality; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor